---
layout: default
title: Lanreotide
parent: 僅模型預測 (L5)
nav_order: 834
evidence_level: L5
indication_count: 5
---

# Lanreotide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **5** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Lanreotide: From Acromegaly/Neuroendocrine Tumors to Hypertrichosis

## One-Sentence Summary

> Lanreotide is a somatostatin analog originally used for acromegaly and neuroendocrine tumors, working by suppressing growth hormone/IGF-1 secretion and cell proliferation.
> The TxGNN model predicts it may be effective for **Hypertrichosis**, but this is currently a **pure computational prediction with zero supporting clinical trials or literature**, and the model's own mechanistic analysis found no known pharmacological link between the drug and this disease.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Acromegaly, neuroendocrine tumors (per drug's known somatostatin-analog mechanism; not separately confirmed by a formal indication record in this evidence pack) |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 (model prediction only — no clinical trials or literature found) |
| Market Status (this jurisdiction) | ✗ Not Marketed |
| Number of Licenses | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the evidence pack (flagged as a High-severity data gap). Based on known drug class information, lanreotide is a somatostatin analog whose established pharmacology is inhibition of growth hormone/IGF-1 secretion and antiproliferative effects, underlying its use in acromegaly and neuroendocrine tumors.

For the top-ranked prediction, hypertrichosis, the model's own mechanistic assessment is explicitly negative: it states there is no known receptor or pathway connection between somatostatin signaling and hair follicle biology, and that the high TxGNN score (0.9997) reflects knowledge-graph structural similarity rather than any pharmacological rationale. In other words, the evidence pack itself concludes this prediction lacks mechanistic support.

The four lower-ranked candidates (odontal/periodontal malformation syndrome, Dandy-Walker malformation syndrome, isolated genetic hair shaft abnormality, Ambras-type congenital hypertrichosis) show the same pattern — high TxGNN scores with no identified mechanistic or clinical connection to somatostatin pharmacology. The 20 literature hits attached to the periodontal-component candidate are general periodontology papers that do not mention lanreotide or somatostatin pathways, and are best interpreted as keyword-matching noise rather than drug-specific evidence.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## US Market Information

The drug is not marketed in this jurisdiction (0 licenses on file), so no marketing authorization records are available.

## Safety Considerations

Please refer to the package insert for safety information. (TFDA label warnings/contraindications and drug-interaction data are currently unavailable — this is flagged as a Blocking data gap that must be resolved before any safety evaluation can proceed.)

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate rests entirely on a TxGNN structural-similarity score (L5), with zero clinical trials, zero supporting literature, and the model's own rationale explicitly stating no known mechanistic link to hypertrichosis. Combined with the absence of any safety/label data for this drug (a blocking gap), there is no basis to advance this candidate at this time.

**To proceed, the following is needed:**
- TFDA label warnings and contraindications (currently blocking — required before any safety pre-screening)
- Confirmed mechanism-of-action data from DrugBank or primary literature
- Independent pharmacological or preclinical rationale connecting somatostatin signaling to hair growth/follicle biology, if this candidate is to be pursued further
- Re-query of clinical trial registries and literature databases periodically, as current searches returned no hits
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

